Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway
A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.
Asset / Drug
Drug and asset intelligence for Mirikizumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.